| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8459441 | Radiotherapy and Oncology | 2017 | 9 Pages |
Abstract
In this multi-institutional study, patients who received SRS for new brain metastases within 5.5Â months after ipilimumab therapy had better intracranial disease control than those who received SRS later. Moreover, higher circulating lymphocyte count was associated with improved intracranial disease control.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yi An, Wen Jiang, Betty Y.S. Kim, Jack M. Qian, Chad Tang, Penny Fang, Jennifer Logan, Neil M. D'Souza, Lauren E. Haydu, Xin A. Wang, Kenneth R. Hess, Harriet Kluger, Isabella C. Glitza, Anita Mahajan, James W. Welsh, Steven H. Lin, James B. Yu,